Results 81 to 90 of about 8,952 (190)

Bullous Pemphigoid [PDF]

Journal of General Internal Medicine, 2012
Barry, Ladizinski, Kachiu Cecelia, Lee
openaire   +2 more sources

Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor in primary care: Case report

Turkish Journal of Family Practice
Bullous pemphigoid is the most common bullous chronic autoimmune skin disease. Recent studies suggest dipeptidyl peptidase-4 inhibitors used in the treatment of type-2 diabetes as possible predisposing agents of bullous pemphigoid.
Kübra Kurt
doaj   +1 more source

The association between COVID‐19 vaccines and bullous pemphigoid risk: A UK population‐based study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Mikolaj Swiderski, Yana Vinogradova, Matthew J. Ridd, Zenas Z. N. Yiu, Antonia Lloyd‐Lavery, Vibhore Prasad, Bruno Gran, Sonia Gran   +7 more
wiley   +1 more source

PD‐L1‐Inhibitor‐Associated Hidradenitis Suppurativa

Journal of Cutaneous Pathology, Volume 53, Issue 9, Page 759-761, September 2026.
Annie Jin, Katherine T. Steele, Emily Y. Chu   +2 more
wiley   +1 more source

Clinicoepidemiological Features of 82 Cases of Bullous Pemphigoid in Tehran, Iran

Acta Medica Iranica, 2018
Bullous Pemphigoid is a chronic immunobullous disease, characterized by subepidermal bulla on the skin and mucosa. The purpose of the present study was to investigate the clinicoepidemiological features of bullous pemphigoid in Iranian patients.
Kamran Balighi, Maryam Daneshpazhooh, Hamidreza Mahmoudi, Maryam Nasimi, Alireza Delavari, Arghavan Azizpour   +5 more
doaj  

Exploring Pruritus in Bullous Pemphigoid: Analysis of QOL Metrics and Potential Biological Mechanisms

JID Innovations
Bullous pemphigoid is a devastating autoimmune blistering disease with need for improved therapeutics. Limited data are available on the overall burden of pruritus and alterations over time; however, treatment of itch-specific pathways may provide novel ...
Olive C. Osuoji, Taryn DeGrazia, Robin Rolader, Emily F. Cole, Katy Lawson, Henry Hilley, Yanyan Xing, Liang Han, Sarah Chisolm, Henry Claussen, Xiaobo Yan, Yuxian Sun, Yuan Liu, Suephy C. Chen, Ron J. Feldman   +14 more
doaj   +1 more source

Two pemphigoid cases with mucous membrane involvement successfully treated with baricitinib

JEADV Clinical Practice
Both bullous pemphigoid and mucous membrane pemphigoid are autoimmune bullous diseases that can be challenging to treat in individual cases. Janus kinase inhibitors have shown efficacy in several autoimmune and inflammatory diseases, although these drugs
Tamás Malkovics, Orsolya N. Horváth, Miklós Sárdy   +2 more
doaj   +1 more source

Mucosal Involvement in Bullous Pemphigoid: Severity Indicator and Associated Clinical Features from a Retrospective Cohort Study. [PDF]

J Inflamm Res
Cui S, Zhang B, Chen F, Liu Y, Zhang J, Jin H, Li L.   +6 more
europepmc   +1 more source

Peristomal bullous pemphigoid: expanding the spectrum of localized presentations. [PDF]

An Bras Dermatol
Ramírez-Bravo F, Contreras CA, Marcet GH, Martínez IW, Urrutia MJ, Castro A.   +5 more
europepmc   +1 more source

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid in an Elderly Woman With Type 2 Diabetes Mellitus: A Case Report. [PDF]

Cureus
Roa Alvarez G, Shuchleib Cukiert M, Hernández Altamirano FR, Berumen Glinz C, Vega Memije ME.   +4 more
europepmc   +1 more source